Education
About Us
Working with TipRanks
Follow Us
Renalytix (RENXF)
OTHER OTC:RENXF
RENXF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.06 - $0.16
Previous CloseN/A
VolumeN/A
Average Volume (3M)41.00
Market Cap
$26.18M
Enterprise Value$34.47M
Total Cash (Recent Filing)$9.63M
Total Debt (Recent Filing)$8.21M
Price to Earnings (P/E)―
Beta-0.70
Next Earnings
Nov 04, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding331,206,020
10 Day Avg. Volume0
30 Day Avg. Volume41
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue14.53
Enterprise Value/Gross Profit73.65
Enterprise Value/Ebitda-1.73
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Renalytix News
RENXF FAQ
What was Renalytix’s price range in the past 12 months?
Renalytix lowest stock price was $0.06 and its highest was $0.16 in the past 12 months.
What is Renalytix’s market cap?
Renalytix’s market cap is $26.18M.
When is Renalytix’s upcoming earnings report date?
Renalytix’s upcoming earnings report date is Nov 04, 2025 which is in 63 days.
How were Renalytix’s earnings last quarter?
Currently, no data Available
Is Renalytix overvalued?
According to Wall Street analysts Renalytix’s price is currently Overvalued.
Does Renalytix pay dividends?
Renalytix does not currently pay dividends.
What is Renalytix’s EPS estimate?
Renalytix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renalytix have?
Renalytix has 331,206,020 shares outstanding.
What happened to Renalytix’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Renalytix?
Currently, no hedge funds are holding shares in RENXF
Company Description
Renalytix
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
Technical Analysis
Ownership Overview
16.10% Insiders
0.05% Other Institutional Investors
83.86% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---